<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25025" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Mesna</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Reddy</surname>
            <given-names>Vamsi</given-names>
          </name>
          <aff>McKinsey &#x00026; Company</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Winston</surname>
            <given-names>Nicole R.</given-names>
          </name>
          <aff>Augusta University Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vamsi Reddy declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nicole Winston declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25025.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This program&#x000a0;discusses&#x000a0;mesna (sodium 2-mercapto-ethane sulfonate), a detoxifying agent employed to avert hemorrhagic cystitis in patients undergoing chemotherapy with high-dose cyclophosphamide or ifosfamide. The discussion centers on mesna's distinctive mechanism of action wherein it undergoes initial inactivation to dimesna (mensa disulfide) within the bloodstream. Once filtered through the kidneys and subsequently excreted into the bladder, mesna undergoes reactivation. In the bladder, the reactivated mesna detoxifies acrolein, a urotoxic byproduct of ifosfamide and cyclophosphamide, thereby mitigating the risk of hemorrhagic cystitis.</p>
        <p>This course explores mesna's indications, potential adverse effects, and contraindications. Moreover, the program extends its purview to off-label applications, pharmacokinetics, monitoring strategies, and clinical toxicology considerations, offering healthcare professionals a comprehensive understanding of mesna's role in patient care.&#x000a0;Adhering to&#x000a0;the American Society of Clinical Oncology (ASCO) guidelines, the CME emphasizes each interprofessional team member's pivotal role in managing hemorrhagic cystitis through mesna administration, ultimately contributing to enhanced patient outcomes and elevated care standards.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Evaluate the mechanism of action of mesna in preventing hemorrhagic cystitis.</p></list-item><list-item><p>Assess the adverse effects associated with mesna administration.</p></list-item><list-item><p>Select appropriate methods for monitoring patients receiving mesna considering individual characteristics.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from mesna therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25025&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25025">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25025.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Mesna&#x000a0;is a prophylactic medication used to reduce the incidence of ifosfamide-induced hemorrhagic cystitis.[1] However, it&#x000a0;is important to recognize that mesna is not indicated to decrease the risk of hematuria due to thrombocytopenia.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Mesna is also used widely as a prophylactic medicine to reduce the incidence of cyclophosphamide-induced hemorrhagic cystitis.</p>
        <p>Additionally, mesna is used off-label for:</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of chemically-assisted dissection of recurrent and residual cholesteatoma&#x000a0;<xref ref-type="bibr" rid="article-25025.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Reduction of the incidence of BK viruria following post-transplantation cyclophosphamide&#x000a0;<xref ref-type="bibr" rid="article-25025.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Inhibition of propylene glycol-induced cholesteatoma formation&#x000a0;<xref ref-type="bibr" rid="article-25025.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of pain following failed back surgery syndrome via epidural injection&#x000a0;<xref ref-type="bibr" rid="article-25025.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of chronic cholesteatomatous otitis media in children&#x000a0;<xref ref-type="bibr" rid="article-25025.r5">[5]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25025.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Mesna (sodium 2-mercapto ethane sulfonate) is a detoxifying agent to prevent hemorrhagic cystitis in patients receiving chemotherapy with high-dose cyclophosphamide or ifosfamide. Mesna initially becomes inactivated to dimesna (mensa disulfide) in the bloodstream. Once it is filtered through the kidneys and excreted into the bladder, it is reactivated. As reactivated mesna concentrates in the bladder, mesna detoxifies acrolein, a urotoxic breakdown product of ifosfamide and cyclophosphamide that accumulates in the bladder. Acrolein stimulates the release of inflammatory mediators interleukin-1 &#x003b2;, TNF-&#x003b1;, and endogenous nitric oxide, inducing vascular dilatation, mucosal edema, and capillary fragility, resulting in hemorrhagic cystitis.<xref ref-type="bibr" rid="article-25025.r6">[6]</xref>&#x000a0;Mesna acts as a sulfhydryl donor that forms a conjugate bond with acrolein and inactivates it, preventing hemorrhagic cystitis or bleeding due to bladder irritation.<xref ref-type="bibr" rid="article-25025.r7">[7]</xref>&#x000a0;Evidence suggests that&#x000a0;this mechanism may include the inhibition of lactoperoxidase (LPO). Lactoperoxidase utilizes hydrogen peroxide (HO) and thiocyanate (SCN) to produce hypothiocyanous acid. Mesna's sulfhydryl group binds stably to LPO within the SCN binding site and thus inhibits function, resulting in the reduction and regulation of local inflammatory effects.<xref ref-type="bibr" rid="article-25025.r8">[8]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:&#x000a0;</bold>After oral administration, peak plasma concentrations are attained within 1.5 to 4 hours for free mesna and 3 to 7 hours for total mesna (mesna plus dimesna and mixed disulfides). Food does not alter the bioavailability of orally administered mesna.</p>
        <p><bold>Distribution:&#x000a0;</bold>The mean apparent volume of distribution for mesna is 0.65 &#x000b1; 0.24 L/kg following IV administration, suggesting distribution to total body water. A fraction of mesna is bound to albumin in plasma.&#x000a0;</p>
        <p><bold>Metabolism:</bold>&#x000a0;Mesna is rapidly oxidized to its major metabolite, mesna disulfide (dimesna), and mixed disulfides. Mixed disulfides have been postulated to play an important role in nephroprotection through inhibiting enzymes &#x003b3;-glutamyltranspeptidase and aminopeptidase N.<xref ref-type="bibr" rid="article-25025.r9">[9]</xref></p>
        <p><bold>Elimination:&#x000a0;</bold>After IV administration of 800 mg of mesna, approximately 33% of the administered dose is excreted in the urine as mesna or dimesna, respectively.</p>
      </sec>
      <sec id="article-25025.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Mesna is available in 100 mg/mL injection, which can be administered as an IV infusion. Mesna is also available as a 400 mg oral tablet. Mesna is usually administered as an injection concurrently with cyclophosphamide or ifosfamide chemotherapy. If the physician deems it necessary after the initial dosage, an oral form (400 mg tablet) is usually administered 2 to 6 hours following subsequent therapy. Due to the strong adverse taste of oral mesna tablets, administering the tablet with juice or food is generally recommended due to the sulfur odor/taste. Patients should be counseled to drink at least 4 cups of liquid daily while taking mesna.<xref ref-type="bibr" rid="article-25025.r10">[10]</xref>&#x000a0;The mesna injection should be diluted in 5% dextrose, 0.45% sodium chloride, 0.9% sodium chloride, or lactated Ringer's injection to attain a final 20 mg/mL concentration.&#x000a0;</p>
        <p>The American Society of Clinical Oncology (ASCO) guidelines recommend following protocols for administering mesna.<xref ref-type="bibr" rid="article-25025.r11">[11]</xref></p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p><bold>Mesna dosing recommendations with standard-dose ifosfamide:</bold>&#x000a0;ASCO recommends that the daily dosage of mesna be calculated to be equivalent to 60% of the total daily dosage of ifosfamide, given as&#x000a0;3 bolus dosage given 15 minutes before and&#x000a0;4 and&#x000a0;8 hours after administration of each dosage of ifosfamide when the ifosfamide dosage is less than 2.5 g/m/day administered as a short infusion. When mesna is used with continuous ifosfamide infusion, it may be given as a bolus dosage equivalent to 20% of the total ifosfamide dosage, followed by a constant infusion of mesna equivalent to 40% of the ifosfamide dosage, given for 12 to 24 hours after completion of the ifosfamide infusion.</p>
        <p><bold>Mesna dosing recommendations with high-dose ifosfamide:</bold>&#x000a0;The efficacy of mesna for preventing urotoxicity with very high-dose ifosfamide (&#x0003e;2.5 g/m/day) has not been established. The half-life of ifosfamide is extended at a higher dosage. Consequently, prolonged mesna dosage regimens may be required for protection against urotoxicity. A higher concentration of ifosfamide (50 mg/mL) is incompatible with mesna and can decrease the stability of ifosfamide.</p>
        <p><bold>Mesna dosing recommendations by the oral route:</bold>&#x000a0;ASCO recommends administering mesna as an IV bolus injection in a dosage of 20% of the ifosfamide dosage at the time of ifosfamide administration; mesna tablets are administered orally in a dosage equal to 40% of the ifosfamide dosage at 2 and 6 hours following each administration of ifosfamide. The total daily dosage of mesna is 100% of the ifosfamide dosage. Repeat the oral dosage or administer IV mesna if vomiting occurs within 2 hours of oral mesna administration. This dosing schedule should be repeated on each day that ifosfamide is administered.</p>
        <p><bold>Mesna recommendations with cyclophosphamide:</bold>&#x000a0;Mesna plus saline diuresis or forced saline diuresis is advised to reduce the incidence of urotoxicity associated with high-dose cyclophosphamide. Mesna injection should not be mixed with cyclophosphamide, cisplatin, carboplatin, and epirubicin. According to KDIGO (kidney disease improving global outcomes) guidelines, mesna should be administered if the cyclophosphamide dosage is considered high.<xref ref-type="bibr" rid="article-25025.r12">[12]</xref></p>
        <p>Epidural injection of mesna reduced pain following failed back surgery syndrome (off-label).<xref ref-type="bibr" rid="article-25025.r4">[4]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:&#x000a0;</bold>No studies have evaluated mesna pharmacokinetics in hepatic impairment.</p>
        <p><bold>Renal impairment:&#x000a0;</bold>No studies have evaluated mesna pharmacokinetics in renal impairment.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>As per the manufacturer's labeling information, it is considered the former FDA pregnancy category B medicine. Clinicians should also inform the patient of the risks associated with ifosfamide/cyclophosphamide therapy. As per ACOG guidelines, besides receiving counseling on preserving fertility before treatment, sexually active young women should also be educated about the hazards of pregnancy during cancer treatment. Clinicians should also guide, and women should also receive counseling regarding effective contraception.<xref ref-type="bibr" rid="article-25025.r13">[13]</xref></p>
        <p><bold>Breastfeeding considerations</bold>: An essential consideration of mesna administration is the breastfeeding status of females of reproductive age.<xref ref-type="bibr" rid="article-25025.r14">[14]</xref>&#x000a0;Whether mesna is present in breast milk is poorly understood; however, benzyl alcohol is often a component of mesna intravenous formulations. The manufacturer indicated that exposure to the breastfeeding infant is unlikely due to maternal metabolism. Nonetheless, benzyl alcohol has been linked to adverse events in infants, and therefore, breastfeeding is not recommended for at least&#x000a0;1 week after the last mesna injection.<xref ref-type="bibr" rid="article-25025.r15">[15]</xref></p>
        <p><bold>Pediatric patients</bold>: A retrospective study explored the outpatient use of ifosfamide and etoposide with mesna in pediatric Ewing sarcoma during the COVID-19 pandemic. No instances of hemorrhagic cystitis were reported.<xref ref-type="bibr" rid="article-25025.r16">[16]</xref>&#x000a0;Mesna is used off-label for pediatric cholesteatoma. Using mesna as a chemical adjunct has shown promise in reducing recurrence rates.&#x000a0;Studies have demonstrated that mesna can be used topically to assist in dissection recurrent and residual cholesteatoma in pediatric patients.<xref ref-type="bibr" rid="article-25025.r17">[17]</xref><xref ref-type="bibr" rid="article-25025.r18">[18]</xref></p>
        <p><bold>Older patients</bold>: Caution is advised in administering mesna in older patients due to potentially reduced liver, kidney, or heart function or other comorbidities. However, there should be no alteration in the ifosfamide-to-mesna ratio.</p>
      </sec>
      <sec id="article-25025.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Mesna in oral and IV administrations is commonly associated with gastrointestinal adverse effects, including&#x000a0;constipation, nausea, vomiting, and abdominal pain.<xref ref-type="bibr" rid="article-25025.r19">[19]</xref>&#x000a0;The most common adverse drug reaction of oral mesna&#x000a0;is dysgeusia.&#x000a0;The patient can often vomit due to the unpalatable taste, and it is a strong recommendation to take mesna with a strong-tasting liquid. Dermatologic reactions range from&#x000a0;fixed drug eruptions to photo-distributed&#x000a0;dermatosis and Stevens-Johnson syndrome.<xref ref-type="bibr" rid="article-25025.r20">[20]</xref><xref ref-type="bibr" rid="article-25025.r21">[21]</xref><xref ref-type="bibr" rid="article-25025.r22">[22]</xref>&#x000a0;Another adverse effect of mesna is hypersensitivity reactions, including rash and leukopenia. Systemic anaphylaxis has&#x000a0;also been reported.<xref ref-type="bibr" rid="article-25025.r23">[23]</xref><xref ref-type="bibr" rid="article-25025.r24">[24]</xref></p>
        <p>
<bold>Laboratory Test Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>No drug-drug interaction studies have been conducted with mesna in clinical trials.</p>
          </list-item>
          <list-item>
            <p>False-negative CPK levels may be reported&#x000a0;due to interference with enzymatic creatinine phosphokinase (CPK) activity tests that utilize a thiol compound for CPK reactivation.</p>
          </list-item>
          <list-item>
            <p>A false-positive reaction for&#x000a0;ascorbic acid&#x000a0;can be observed in the presence of mesna (Tillman's&#x000a0;reagent-based urine screening tests).<xref ref-type="bibr" rid="article-25025.r25">[25]</xref></p>
          </list-item>
          <list-item>
            <p>False positive tests for urinary ketones may occur in patients&#x000a0;who are given mesna when using nitroprusside sodium-based urine tests (dipstick tests).<xref ref-type="bibr" rid="article-25025.r26">[26]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25025.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Mesna prophylaxis is contraindicated in patients with hypersensitivity to thiol compounds and those with adverse reactions associated with a prior mesna administration.<xref ref-type="bibr" rid="article-25025.r27">[27]</xref>&#x000a0;Mesna prophylaxis is also contraindicated in patients with hypersensitivity or previous adverse reactions to benzyl alcohol (an excipient used in mesna).<xref ref-type="bibr" rid="article-25025.r15">[15]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <p>Severe and fatal reactions, including "gasping syndrome," have been documented in premature neonates and low-birth-weight infants with benzyl alcohol. Clinical features include neurological deterioration, intracranial hemorrhage, hematological abnormalities, liver and kidney issues, hypotension, bradycardia, and cardiovascular collapse. Premature neonates and low-birth-weight infants may have a higher risk due to difficulties in breaking down benzyl alcohol. The exact minimum amount causing toxicity is unknown. Mesna injection contains benzyl alcohol and should be avoided in these infants due to potential harm.<xref ref-type="bibr" rid="article-25025.r28">[28]</xref></p>
      </sec>
      <sec id="article-25025.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Along with mesna administration, providers must monitor urine for signs of hematuria and monitor urine output and hydration status. Breakthrough hematuria is a rare event, even on mesna prophylaxis. If the physician deems mesna administration subtherapeutic and the hemorrhagic cystitis is still present, an additional IV bolus or oral tablet may be administered. Monitoring patients for signs/symptoms of hypersensitivity or dermatologic toxicity is essential. Reactions associated with mesna are rare. However, mesna has the potential to lead to severe hypersensitivity reactions, including anaphylactic shock.<xref ref-type="bibr" rid="article-25025.r21">[21]</xref>&#x000a0;Pregnancy tests should be performed for women of reproductive potential before initiating the medicine, as it is often used with other chemotherapeutic treatments.<xref ref-type="bibr" rid="article-25025.r13">[13]</xref></p>
      </sec>
      <sec id="article-25025.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>The product labeling describes signs of overdose observed in a clinical trial involving 11 patients who received intravenous mesna at dosages ranging from 10 mg/kg to 66 mg/kg daily for 3 to 5 days with ifosfamide/ cyclophosphamide. Clinical features included nausea, vomiting, diarrhea, and fever. Postmarketing studies with mesna&#x000a0;dosage&#x000a0;of 4.5 g to 6.9 g&#x000a0;recorded hypersensitivity reactions, including mild hypotension, exacerbation of asthma, rash, and flushing.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>There is no indicated antidote to mesna overdose. Mesna administration is usually&#x000a0;via IV bolus or an oral tablet, and therefore, unlike a drip, it cannot be immediately stopped with the appearance of adverse effects. If a hypersensitivity reaction is present after administration, supportive care with fluid administration is recommended.<xref ref-type="bibr" rid="article-25025.r24">[24]</xref>&#x000a0;The recommendation is to consult&#x000a0;with a medical toxicologist or poison control center, which is helpful in complex cases.<xref ref-type="bibr" rid="article-25025.r29">[29]</xref></p>
      </sec>
      <sec id="article-25025.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing adverse reactions associated with drug administration requires an interprofessional team of healthcare professionals, including a nurse, laboratory technologists, pharmacists, and several&#x000a0;clinicians involved in patient care. Studies have shown that interprofessional communication in the healthcare environment significantly improves patient outcomes and healthcare cost burden regarding repeat imaging, labs, and advanced testing.<xref ref-type="bibr" rid="article-25025.r30">[30]</xref><xref ref-type="bibr" rid="article-25025.r31">[31]</xref><xref ref-type="bibr" rid="article-25025.r32">[32]</xref></p>
        <p>The most common adverse effect of oral mesna administration is bad taste.&#x000a0;Unfortunately, this can affect patient compliance with medication. In addition, if patients do not adhere to the regimen, it may lead to urinary tract irritation and hemorrhagic cystitis associated with ifosfamide and cyclophosphamide. To avoid this, healthcare providers at every level must effectively communicate the importance of taking this drug and discuss strategies to help make it more palatable. Examples of such measures include administering the medication with a strong-tasting liquid such as grape juice or crushing up the oral drug and mixing it into more palatable foods such as apple sauce.</p>
        <p>However, beyond the taste, there are additional adverse effects associated with mesna. Without proper management and monitoring, these can lead to more dire consequences, such as hypersensitivity reactions.&#x000a0;As mesna is not a drug commonly associated with these serious adverse effects, healthcare providers are prone to take these reactions for granted or not consider mesna the culprit. When patients present with any adverse reaction to the nursing staff, they must promptly notify&#x000a0;a physician.</p>
        <p>Once notified, it is also&#x000a0;important that clinicians communicate with urologists for hemorrhagic cystitis and immunologists for hypersensitivity reactions. Anaphylaxis requires coordination between emergency department physicians and critical care physicians. In overdose, consultation with a medical toxicologist is crucial. Pharmacists should verify the dosing and schedule of mesna and ifosfamide. Numerous case series have been&#x000a0;associated with the adverse effects of mesna usage.<xref ref-type="bibr" rid="article-25025.r22">[22]</xref><xref ref-type="bibr" rid="article-25025.r24">[24]</xref><xref ref-type="bibr" rid="article-25025.r23">[23]</xref>&#x000a0;Therefore, collaboration and coordination between the interprofessional team consisting of clinicians (MDs, DOs, NPs, PAs), specialists, nursing staff, and pharmacists are&#x000a0;crucial to improving patient outcomes related to mesna therapy.</p>
      </sec>
      <sec id="article-25025.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25025&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25025">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25025/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25025">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25025.s11">
        <title>References</title>
        <ref id="article-25025.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de la Torre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Villamor</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Chemically Assisted Dissection With Sodium 2-Mercaptoethanesulfonate (MESNA) in the Surgical Management of Pediatric Cholesteatoma.</article-title>
            <source>Otol Neurotol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>40</volume>
            <issue>5</issue>
            <fpage>645</fpage>
            <page-range>645-650</page-range>
            <pub-id pub-id-type="pmid">31083092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaiswal</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Singhal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Thatai</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhagwati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aiyer</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chakrabarti</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Impact of extended infusional mesna prophylaxis on the incidence of BK viruria and hemorrhagic cystitis following post-transplantation cyclophosphamide and CTLA4Ig-based haploidentical transplantation.</article-title>
            <source>Ann Hematol</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>99</volume>
            <issue>4</issue>
            <fpage>839</fpage>
            <page-range>839-845</page-range>
            <pub-id pub-id-type="pmid">32025839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ismi</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Karabulut</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Bal</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Vayisoglu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Unal</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Single dose intratympanic mesna application inhibits propylene glycol induced cholesteatoma formation.</article-title>
            <source>J Laryngol Otol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>131</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-220</page-range>
            <pub-id pub-id-type="pmid">27995828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carassiti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Martino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Centonze</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Quattrocchi</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Caldaria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Agr&#x000f2;</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Denaro</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Failed back surgery syndrome: a new strategy by the epidural injection of MESNA.</article-title>
            <source>Musculoskelet Surg</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>102</volume>
            <issue>2</issue>
            <fpage>179</fpage>
            <page-range>179-184</page-range>
            <pub-id pub-id-type="pmid">29098646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de la Torre Gonz&#x000e1;lez</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Huante-Guido</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vel&#x000e1;zquez Guadarrama</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Preciado</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pati&#x000f1;o L&#x000f3;pez</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Changes in biofilm in chronic cholesteatomatous otitis media in children following the application of sodium 2-mercaptoethanesulfonate (MESNA).</article-title>
            <source>Int J Pediatr Otorhinolaryngol</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>110</volume>
            <fpage>48</fpage>
            <page-range>48-52</page-range>
            <pub-id pub-id-type="pmid">29859586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manikandan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dorairajan</surname>
                <given-names>LN</given-names>
              </name>
            </person-group>
            <article-title>Hemorrhagic cystitis: A challenge to the urologist.</article-title>
            <source>Indian J Urol</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>159</fpage>
            <page-range>159-66</page-range>
            <pub-id pub-id-type="pmid">20877590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaw</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>MI</given-names>
              </name>
            </person-group>
            <article-title>Mesna--a short review.</article-title>
            <source>Cancer Treat Rev</source>
            <year>1987</year>
            <month>Jun</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>67</fpage>
            <page-range>67-86</page-range>
            <pub-id pub-id-type="pmid">3119211</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jahanbakhsh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dekhne</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kohan-Ghadr</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Bai</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Awonuga</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Abu-Soud</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>The inhibition of lactoperoxidase catalytic activity through mesna (2-mercaptoethane sodium sulfonate).</article-title>
            <source>J Inorg Biochem</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>203</volume>
            <fpage>110911</fpage>
            <pub-id pub-id-type="pmid">31734539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cutler</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Velenosi</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Bodalia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>House</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Urquhart</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Enzymatic and non-enzymatic mechanisms of dimesna metabolism.</article-title>
            <source>Amino Acids</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>511</fpage>
            <page-range>511-23</page-range>
            <pub-id pub-id-type="pmid">25488427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sannu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Radha</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Padmakumari Mony</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Prahladan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>FV</given-names>
              </name>
            </person-group>
            <article-title>Ifosfamide-Induced Malignancy of Ureter and Bladder.</article-title>
            <source>Cureus</source>
            <year>2017</year>
            <month>Aug</month>
            <day>22</day>
            <volume>9</volume>
            <issue>8</issue>
            <fpage>e1594</fpage>
            <pub-id pub-id-type="pmid">29062626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hensley</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Hagerty</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Kewalramani</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Meropol</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Emami</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gradishar</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Thigpen</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Trotti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>von Hoff</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schuchter</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants.</article-title>
            <source>J Clin Oncol</source>
            <year>2009</year>
            <month>Jan</month>
            <day>01</day>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>127</fpage>
            <page-range>127-45</page-range>
            <pub-id pub-id-type="pmid">19018081</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group</collab>
            <article-title>KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases.</article-title>
            <source>Kidney Int</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>100</volume>
            <issue>4S</issue>
            <fpage>S1</fpage>
            <page-range>S1-S276</page-range>
            <pub-id pub-id-type="pmid">34556256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <article-title>ACOG Committee Opinion No. 747 Summary: Gynecologic Issues in Children and Adolescent Cancer Patients and Survivors.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>132</volume>
            <issue>2</issue>
            <fpage>535</fpage>
            <page-range>535-536</page-range>
            <pub-id pub-id-type="pmid">30045207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ninane</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baurain</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Kraker</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ferster</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Trouet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cornu</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>1989</year>
            <volume>24 Suppl 1</volume>
            <fpage>S2</fpage>
            <page-range>S2-6; discussion S7</page-range>
            <pub-id pub-id-type="pmid">2503256</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sridharan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Al Jufairi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Al Daylami</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Al Ansari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Qader</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pasha</surname>
                <given-names>SAA</given-names>
              </name>
            </person-group>
            <article-title>Possible effects of excipients used in the parenteral drugs administered in critically ill adults, children, and neonates.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>1625</fpage>
            <page-range>1625-1640</page-range>
            <pub-id pub-id-type="pmid">32767900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarfraz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saeed</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Feasibility and safety of outpatient administration of ifosfamide and etoposide for pediatric patients with Ewing sarcoma in a resource-limited setting amid the COVID-19 pandemic.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2022</year>
            <month>May</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>e29595</fpage>
            <pub-id pub-id-type="pmid">35234343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orobello</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>BK</given-names>
              </name>
            </person-group>
            <article-title>Updates in paediatric cholesteatoma.</article-title>
            <source>Curr Opin Otolaryngol Head Neck Surg</source>
            <year>2022</year>
            <month>Dec</month>
            <day>01</day>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>422</fpage>
            <page-range>422-425</page-range>
            <pub-id pub-id-type="pmid">36165030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>E&#x0011f;ilmez</surname>
                <given-names>OK</given-names>
              </name>
              <name>
                <surname>K&#x000f6;kten</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kalc&#x00131;o&#x0011f;lu</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Do&#x0011f;an Ekici</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tekin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Electrophysiological and Histopathological Evaluation of Effects of Sodium-2 Mercaptoethanesulfonate Used for Middle Ear Surgery on Facial Nerve Functions.</article-title>
            <source>J Int Adv Otol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>239</fpage>
            <page-range>239-244</page-range>
            <pub-id pub-id-type="pmid">29283098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matz</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.</article-title>
            <source>Urology</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>100</volume>
            <fpage>16</fpage>
            <page-range>16-19</page-range>
            <pub-id pub-id-type="pmid">27566144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lebrun-Vignes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Le Forestier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Franc&#x000e8;s</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Fixed Drug Eruption Due to Mesna.</article-title>
            <source>J Investig Allergol Clin Immunol</source>
            <year>2015</year>
            <volume>25</volume>
            <issue>6</issue>
            <fpage>444</fpage>
            <page-range>444-5</page-range>
            <pub-id pub-id-type="pmid">26817144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Keefe</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mesna-induced photodistributed dermatosis.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>358</fpage>
            <page-range>358-60</page-range>
            <pub-id pub-id-type="pmid">22103595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khaw</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Downie</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Waters</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Ashley</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Heath</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>49</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-3</page-range>
            <pub-id pub-id-type="pmid">16333822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ercan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aysegul</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Burcak</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ilknur</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Sepsis like acute hypersensitivity syndrome related to mesna.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>9</issue>
            <fpage>e393</fpage>
            <page-range>e393-e394</page-range>
            <pub-id pub-id-type="pmid">28271573</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robertson</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Looking beyond the angiotensin receptor blocker: A case of anaphylaxis to mesna.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>324</fpage>
            <page-range>324-5</page-range>
            <pub-id pub-id-type="pmid">27424127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nikolac Gabaj</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Miler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Unic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Milevoj Kopcinovic</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vrtaric</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Culej</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Ascorbic acid in urine still compromises urinalysis results.</article-title>
            <source>Ann Clin Biochem</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-68</page-range>
            <pub-id pub-id-type="pmid">31569954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simerville</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Maxted</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Pahira</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Urinalysis: a comprehensive review.</article-title>
            <source>Am Fam Physician</source>
            <year>2005</year>
            <month>Mar</month>
            <day>15</day>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>1153</fpage>
            <page-range>1153-62</page-range>
            <pub-id pub-id-type="pmid">15791892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimogori</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Araki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shibazaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tuda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Nonimmediate allergic reactions induced by Mesna.</article-title>
            <source>J Gen Fam Med</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>285</fpage>
            <page-range>285-287</page-range>
            <pub-id pub-id-type="pmid">29264044</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fukuda</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kamidani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kitagawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ogura</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Complex poisoning mainly with benzyl alcohol complicated by paralytic ileus: a case report.</article-title>
            <source>Int J Emerg Med</source>
            <year>2022</year>
            <month>Jul</month>
            <day>04</day>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <pub-id pub-id-type="pmid">35787785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Danagoulian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Menke</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Saul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abesamis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pizon</surname>
                <given-names>AF</given-names>
              </name>
            </person-group>
            <article-title>The Effect of a Medical Toxicology Inpatient Service in an Academic Tertiary Care Referral Center.</article-title>
            <source>J Med Toxicol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-21</page-range>
            <pub-id pub-id-type="pmid">30353414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Leary</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Manojlovich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>MV</given-names>
              </name>
            </person-group>
            <article-title>Redesigning systems to improve teamwork and quality for hospitalized patients (RESET): study protocol evaluating the effect of mentored implementation to redesign clinical microsystems.</article-title>
            <source>BMC Health Serv Res</source>
            <year>2019</year>
            <month>May</month>
            <day>08</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>293</fpage>
            <pub-id pub-id-type="pmid">31068161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golom</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Schreck</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>The Journey to Interprofessional Collaborative Practice: Are We There Yet?</article-title>
            <source>Pediatr Clin North Am</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>65</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-12</page-range>
            <pub-id pub-id-type="pmid">29173710</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25025.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bentley</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Javanparast</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Interprofessional teamwork in comprehensive primary healthcare services: Findings from a mixed methods study.</article-title>
            <source>J Interprof Care</source>
            <year>2018</year>
            <month>May</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>274</fpage>
            <page-range>274-283</page-range>
            <pub-id pub-id-type="pmid">29182411</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
